Du Life Cycle Management pour Neupro - NEUTRE - OC 69€
UCB annonce ce matin sa collaboration avec la société Neuropore Therapies dans le but de développer puis commercialiser un nouveau médicament dans la prise en charge des patients atteints de la maladie de Parkinson. En contrepartie de recevoir une licence mondiale de commercialisation du principal produit de la société (NPT200-11), UCB versera un paiement initial de 20m$ suivi de certains paiements d’étapes en fonction de l’avancée du médicament pouvant atteindre un montant total de 460m$. Bien que ce médicament soit actuellement extrêmement « early stage » et ne devrait pas conduire le consensus à modifier ses estimations, il viendrait en complément de Neupro dans un but d’un « Life Cycle Management ». Nous maintenons à ce stade notre recommandation à NEUTRE sur la valeur avec un objectif de cours de 69€.UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.